CN113785052B - 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途 - Google Patents

新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途 Download PDF

Info

Publication number
CN113785052B
CN113785052B CN202080020112.7A CN202080020112A CN113785052B CN 113785052 B CN113785052 B CN 113785052B CN 202080020112 A CN202080020112 A CN 202080020112A CN 113785052 B CN113785052 B CN 113785052B
Authority
CN
China
Prior art keywords
leu
pro
gly
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080020112.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113785052A (zh
Inventor
T·伯姆
B·伊尔马
N·博特
E·格卢多瓦茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vienna University Of Natural Resources And Life Sciences
University of Veterinary Medicine Vienna
Original Assignee
Vienna University Of Natural Resources And Life Sciences
University of Veterinary Medicine Vienna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vienna University Of Natural Resources And Life Sciences, University of Veterinary Medicine Vienna filed Critical Vienna University Of Natural Resources And Life Sciences
Publication of CN113785052A publication Critical patent/CN113785052A/zh
Application granted granted Critical
Publication of CN113785052B publication Critical patent/CN113785052B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022—Diamine oxidase (1.4.3.22)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Library & Information Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
CN202080020112.7A 2019-02-19 2020-02-18 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途 Active CN113785052B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19157932.5 2019-02-19
EP19157932 2019-02-19
PCT/EP2020/054197 WO2020169577A1 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Publications (2)

Publication Number Publication Date
CN113785052A CN113785052A (zh) 2021-12-10
CN113785052B true CN113785052B (zh) 2024-06-28

Family

ID=65493995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080020112.7A Active CN113785052B (zh) 2019-02-19 2020-02-18 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途

Country Status (14)

Country Link
US (1) US20220145269A1 (enExample)
EP (1) EP3927817B1 (enExample)
JP (1) JP7792252B2 (enExample)
KR (1) KR20210132650A (enExample)
CN (1) CN113785052B (enExample)
AU (1) AU2020225319B2 (enExample)
BR (1) BR112021015865A2 (enExample)
CA (1) CA3130751A1 (enExample)
EA (1) EA202192305A1 (enExample)
ES (1) ES3041133T3 (enExample)
IL (1) IL285452B2 (enExample)
MX (1) MX2021010050A (enExample)
SG (1) SG11202107659SA (enExample)
WO (1) WO2020169577A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
EP4496488A4 (en) * 2022-03-21 2025-11-26 Cedars Sinai Medical Center METHODS AND COMPOSITIONS FOR THE SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE INTESTINAL MICROBIOME
IL317379A (en) * 2022-06-03 2025-02-01 Oyster Point Pharma Inc AAV vector encoding diamine oxidase and its uses
EP4782002A1 (en) * 2025-01-27 2026-07-29 DR Healthcare S.L.U. Diamine oxidase (dao) for use in the treatment of infertility
CN121975758B (zh) * 2026-04-02 2026-07-14 华中科技大学同济医学院附属同济医院 组胺氧化酶蛋白及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122254A2 (en) * 2021-12-22 2023-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods to elicit desire to mate and mating behavior

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
IT1317067B1 (it) * 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2536016C (en) * 2002-08-16 2017-01-10 Paul L. Deangelis Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
AT502098B8 (de) * 2004-07-07 2007-06-15 Albert Dr Missbichler Diaminooxidase-hältige zusammensetzung
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2012028891A1 (en) * 2010-09-02 2012-03-08 Debreceni Egyetem Perorally applicable preparation containing histaminase of vegetable origin, resistant to pepsin and trypsin and a process for producing it
JP2014518632A (ja) * 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
AU2015332533B2 (en) * 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122254A2 (en) * 2021-12-22 2023-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods to elicit desire to mate and mating behavior

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Glycosylation site Asn168 is important for slow in vivo clearance of recombinant human diamine oxidase heparin-binding motif mutants";Gludovacz 等;《GLYCOBIOLOGY》;第32卷(第5期);404-413 *
"Structure and Inhibition of Human Diamine Oxidase";McGrath 等;《BIOCHEMISTRY》;第48卷(第41期);摘要, 第9810页左栏注释, 第9816页右栏第3段 *
"拟南芥二胺氧化酶（CuAOζ）及其转录因子MYB响应生长素信号的分子机理";王清;《中国优秀硕士学位论文全文数据库 基础科学辑》(第7期);A006-123 *

Also Published As

Publication number Publication date
ES3041133T3 (en) 2025-11-07
EP3927817C0 (en) 2025-08-20
AU2020225319B2 (en) 2025-05-29
KR20210132650A (ko) 2021-11-04
US20220145269A1 (en) 2022-05-12
BR112021015865A2 (pt) 2021-10-05
SG11202107659SA (en) 2021-09-29
WO2020169577A1 (en) 2020-08-27
CA3130751A1 (en) 2020-08-27
EP3927817B1 (en) 2025-08-20
CN113785052A (zh) 2021-12-10
IL285452B2 (en) 2025-07-01
IL285452A (en) 2021-09-30
MX2021010050A (es) 2021-09-21
JP2022520862A (ja) 2022-04-01
EP3927817A1 (en) 2021-12-29
AU2020225319A1 (en) 2021-10-14
IL285452B1 (en) 2025-03-01
JP7792252B2 (ja) 2025-12-25
EA202192305A1 (ru) 2021-12-08

Similar Documents

Publication Publication Date Title
AU2020225319B2 (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
CN106573966B (zh) 用于治疗代谢异常的组合物和方法
TWI436776B (zh) Ｆｇｆ２１突變體及其用途
AU2017294551B2 (en) Soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides and uses thereof
US20200040051A1 (en) Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
WO2013130684A1 (en) Xten-folate conjugate compositions and methods of making same
US20160237133A1 (en) Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
WO2016048995A2 (en) Fgf19 truncations and mutants and uses thereof
US20180057554A1 (en) Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose
AU2014314222B2 (en) Stable polypeptides binding to human complement C5
US20170291931A1 (en) Fgf2 truncations and mutants and uses thereof
JP2013515474A (ja) 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
US20260035706A1 (en) Fusion polypeptides
JP2009519006A (ja) 改善された色素上皮由来因子変異体及びその使用
WO2017127493A1 (en) Fgf2 truncations and mutants and uses thereof
HK40064258A (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
HK40064258B (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
US6893844B1 (en) DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7361486B2 (en) Polynucleotide, vector, host cell and method for producing human hepatoma-derived growth factor 5 polypeptide
CN1318100A (zh) 新的人肝癌细胞衍生生长因子编码序列、其编码的多肽及制备方法
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064258

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant